Robalzotan

Robalzotan (NAD-​299) is a potent and selective 5-Hydroxytryptamine 1A (5-HT1A) inhibitor. Robalzotan increases the firing rate of 5-HT cells. Robalzotan induces 5-HT1A receptor occupancy. Robalzotan has the potential for the research of a cholinergic deficit in the central -nervous system^[1][2][3]. In Vivo: Robalzotan (1-100 µg/kg; i.v.) significantly increases the activity of such neurons at 5 µg/kg in rats, and reverses the acute inhibitory effect of citalopram (HY-121203) (300 µg/kg i.v.) or paroxetine (HY-122272) (100 µg/kg, i.v.) on the activity of 5-HT neurons in the dorsal raphe nucleus in rats^[1].
Robalzotan (5, 50 µg/kg; i.v.) increases the firing rate of the 5-HT cells^[1].
Robalzotan (2-100 µg/kg; i.v.) occupies 5-HT1A receptors in a dose-dependent in monkeys^[2].
Robalzotan (0.3; 1 and 3 µmol/kg s.c) causes a dose-dependent increase of extracellular ACh levels in the rat FC^[3].